Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T cell vaccine AlloStim - Immunovative Therapies

Next Previous
X
Search
Drug Profile

T cell vaccine AlloStim - Immunovative Therapies

Alternative Names: AlloStim; AlloStim-7; AlloStim-8; AlloStim-9; Bioengineered allogeneic immune cells (AlloStim); InSituStim; InSituVax; Intentionally mis-matched, allogeneic Th1 memory Cells (AlloStim) conjugated With CD3/CD28-coated microbeads; Mis-matched immune cell therapy (AlloStim) - Immunovative Therapies; Personalized anti-tumour vaccine - Immunovative Therapies; StimVax®

Latest Information Update: 21 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunovative Therapies
  • Developer Immunovative Therapies; Mirror Biologics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; T lymphocyte cell therapies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Liver cancer
  • Phase II Colorectal cancer
  • Phase I/II Solid tumours; Viral infections
  • No development reported Haematological malignancies

Most Recent Events

  • 16 Aug 2024 Mirror Biologics plans phase II COMUNITY trial in Colorectal Cancer (Metastatic disease, Late-stage disease and Second-line therapy and greater) in US (NCT06557278)
  • 01 Aug 2023 Phase-II/III clinical trials in Liver cancer (First-line therapy, Late-stage disease) in Malaysia, Thailand (IV) (NCT05033522)
  • 01 Apr 2023 Immunovative Therapies and Mirror Biologics complete the phase I/II ALLOPRIME trial in Viral infections (Prevention, In the elderly) in USA (Intradermal) (NCT04441047)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top